Provided by Tiger Trade Technology Pte. Ltd.

Coeur Mining

20.97
-0.1400-0.66%
Post-market: 21.030.0600+0.29%19:59 EDT
Volume:45.81M
Turnover:968.01M
Market Cap:21.70B
PE:17.62
High:21.88
Open:21.75
Low:20.96
Close:21.11
52wk High:27.77
52wk Low:11.50
Shares:1.04B
Float Shares:1.03B
Volume Ratio:1.23
T/O Rate:4.47%
Dividend:0.02
Dividend Rate:0.10%
EPS(TTM):1.19
EPS(LYR):0.9500
ROE:12.85%
ROA:7.21%
PB:2.09
PE(LYR):22.07

Loading ...

LEADS BIOLABS-B (09887): Phase 3 Trial for VELIXIN™ (PD-L1/4-1BB Bispecific Antibody Opatumilab) in Advanced Extrapulmonary Neuroendocrine Carcinoma Receives CDE Approval

Stock News
·
May 19

A Look At Coeur Mining (CDE) Valuation After Recent Share Price Volatility

Simply Wall St.
·
May 17

BUZZ-Silver miners fall on rising yields, stronger dollar

Reuters
·
May 15

Gold, Silver Stocks and ETFs Sink With AGQ Down 18%, SLV Down 9%

Tiger Newspress
·
May 15

Hecla Mining Down 8.2%, Coeur Mining Falls 8%, Silvercorp Metals Drops 9.3%, Endeavour Silver Down 8.8%

THOMSON REUTERS
·
May 15

Coeur Mining Initiates First Dividend and Governance Updates

TIPRANKS
·
May 14

Coeur Mining Declares Semiannual Dividend

Dow Jones
·
May 14

Coeur Mining initiates 2c per share semi-annual dividend

TIPRANKS
·
May 14

Coeur Mining Sets Semi-Annual Dividend of $0.02 a Share, Payable June 10 to Shareholders of Record on May 22

MT Newswires Live
·
May 14

Press Release: Coeur Declares Inaugural Dividend

Dow Jones
·
May 14

Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody

prnewswire
·
May 13

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

GlobeNewswire
·
May 13

RBC Capital Remains a Buy on Coeur Mining (CDE)

TIPRANKS
·
May 12

Gold, Silver Stocks and ETFs Jump With AGQ up 11%

Tiger Newspress
·
May 11

Stock Track | Coeur Mining Soars 7.38% Intraday on Reaffirmed Production Guidance and Gold Sector Strength

Stock Track
·
May 11

A Look At Coeur Mining (CDE) Valuation As Record Q1 Results And New Capital Returns Draw Focus

Simply Wall St.
·
May 10

Policy Support for Pediatric Medication Market Gains Momentum, Listed Companies Actively Expanding Presence

Deep News
·
May 09

Coeur Mining price target raised to $25 from $24 at Roth Capital

TIPRANKS
·
May 09

Tianyu Pharma's Reflux Esophagitis API Clears CDE Review

MT Newswires Live
·
May 08

Coeur Mining (CDE) Net Margin Strength Tests Bullish Earnings Narratives After Q1 2026 Results

Simply Wall St.
·
May 08